
OSIMIS
OSIMIS
1 Projects, page 1 of 1
Open Access Mandate for Publications and Research data assignment_turned_in Project2023 - 2027Partners:FHG, VHIO, RADBOUDUMC, RIBERA SALUD SA, OSIMIS +13 partnersFHG,VHIO,RADBOUDUMC,RIBERA SALUD SA,OSIMIS,UKA,EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG,VHIO,StratifAI,EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG,StratifAI,OSIMIS,TUD,PRIVATE GENERAL MATERNITY GENECOLOGICAL AND CHILDRENS HOSPITAL,UKA,UMC,PRIVATE GENERAL MATERNITY GENECOLOGICAL AND CHILDRENS HOSPITAL,RIBERA SALUD SAFunder: European Commission Project Code: 101057091Overall Budget: 8,691,760 EURFunder Contribution: 8,691,760 EURArtifArtificial Intelligence (AI) will revolutionize healthcare as its diagnostic performance approaches that of clinical experts. In particular, in cancer screening, AI helps patients to make better-informed decisions and reduce medical error. However, this requires large datasets whose collection faces severe practical, ethical and legal obstacles. These obstacles can be overcome with swarm learning (SL) where partners jointly train AI models without sharing any data. Yet, access to SL technology is seriously limited because no studies have implemented SL in a true multinational setup, no practically usable implementation of SL is available, researchers & healthcare providers have no experience with setting up SL networks and policymakers are currently unaware of the broader implications of SL. ODELIA will address & solve these issues: ODELIA will build the first open-source software framework for SL, providing an assembly line for the streamlined development of AI solutions. To serve as a blueprint for future SL-based AI systems, ODELIA partners collaborate as a swarm to develop the first clinically useful AI algorithm for the detection of breast cancer in magnetic resonance imaging (MRI). The size of ODELIA's distributed database will exceed all previous studies and ODELIA's AI models will reach expert-level performance for breast cancer screening. Thereby, ODELIA will not only deliver a useful medical application, but prove the clinical benefit of SL in terms of accelerated development, increased performance and robust generalizability to ultimately save thousands of lives of European patients. ODELIA's success will push partners to serve as nuclei for the exponential growth of the SL network and extend SL to a multitude of medical applications. Thus, patients, healthcare providers and citizens in Europe will be provided with a digital infrastructure that enables development of expert-level AI tools on big data without compromising data safety and data privacy.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_____he::37ae0617d9b743303f88f674a39c2107&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_____he::37ae0617d9b743303f88f674a39c2107&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu